Nasdaq · CIK 0000872589
REGN REGENERON PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing 39 d ago. Close $746.54 on Oct 9, 2026, +35% from the 52-week low and -12% from the high.
Last 90 days
Net insider value
-$2.3M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$2.3M by 2 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
REGNOct 9, 2026 · close 746.54
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at REGENERON PHARMACEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Kathryn Guarini director sell | $340k 400 shares | -40% | +54% from low0% from high | |
| 33Weak | Marion McCourt EVP Commercial sell | $2.0M 2,346 shares | -16% | +54% from low0% from high | |
| 3Weak | Marion McCourt EVP Commercial sell | $845k 1,000 shares | -7% | - |
Congressional trades
14 trades in REGN disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Alan Armstrong Senate · R-OK | Purchase | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Mar 27 / Jul 21 116 days after the trade | eFD |
Gilbert Ray Cisneros, Jr. House · D-CA | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | May 15 / Jun 8 24 days after the trade | Clerk |
Julia Letlow House · R-LA | Purchase | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Feb 12 / Mar 12 28 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Nov 18, 2025 / Dec 15, 2025 27 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Purchase | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | May 15, 2025 / Jun 9, 2025 25 days after the trade | Clerk |
Byron Donalds House · R-FL | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Apr 10, 2025 / May 24, 2025 44 days after the trade | Clerk |
Byron Donalds House · R-FL | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Apr 10, 2025 / May 24, 2025 44 days after the trade | Clerk |
Julie Johnson House · D-TX | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Apr 1, 2025 / May 14, 2025 43 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Apr 8, 2025 / May 8, 2025 30 days after the trade | Clerk |
Jefferson Shreve House · R-IN | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $15k to $50k | Apr 7, 2025 / May 8, 2025 31 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Feb 25, 2025 / Mar 27, 2025 30 days after the trade | Clerk |
Julie Johnson House · D-TX | Partial sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Feb 12, 2025 / Mar 12, 2025 28 days after the trade | Clerk |
Julie Johnson House · D-TX | Purchase | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Jan 15, 2025 / Feb 12, 2025 28 days after the trade | Clerk |
Josh Gottheimer House · D-NJ | Sale | REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Jan 24, 2025 / Feb 10, 2025 17 days after the trade | Clerk |
Transactions
The last 47 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Kathryn Guarini director | MOption exercise Common Stock10b5-1 | +400 | $719.37 | $288k | 1,003 | 39 d ago |
| Sep 2, 2026 | Marion McCourt EVP Commercial | SOpen-market sale Common Stock10b5-1 | -1,215 | $850.00 | $1.0M | 13,134 | 39 d ago |
| Sep 2, 2026 | Kathryn Guarini director | SOpen-market sale Common Stock10b5-1 | -400 | $850.00 | $340k | 603 | 39 d ago |
| Sep 3, 2026 | Marion McCourt EVP Commercial | SOpen-market sale Common Stock10b5-1 | -1,131 | $857.39 | $970k | 12,003 | 39 d ago |
| Sep 2, 2026 | Kathryn Guarini director | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 1,158 | 39 d ago |
| Jan 2, 2025 | N Anthony Coles director | AGrant or award Common Stock | +166 | $0.00 | $0 | 1,559 | Jan 6, 2025 |
| Jan 2, 2025 | Kathryn Guarini director | AGrant or award Common Stock | +166 | $0.00 | $0 | 448 | Jan 6, 2025 |
| Jan 2, 2025 | Joseph L Goldstein director | AGrant or award Common Stock | +166 | $0.00 | $0 | 6,548 | Jan 6, 2025 |
| Jan 2, 2025 | Bonnie L Bassler director | AGrant or award Common Stock | +166 | $0.00 | $0 | 1,548 | Jan 6, 2025 |
| Jan 2, 2025 | Michael S Brown director | AGrant or award Common Stock | +166 | $0.00 | $0 | 1,548 | Jan 6, 2025 |
| Jan 2, 2025 | Bonnie L Bassler director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +1,958 | $0.00 | $0 | 1,958 | Jan 6, 2025 |
| Jan 2, 2025 | N Anthony Coles director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +1,958 | $0.00 | $0 | 1,958 | Jan 6, 2025 |
| Jan 2, 2025 | Joseph L Goldstein director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +1,958 | $0.00 | $0 | 1,958 | Jan 6, 2025 |
| Jan 2, 2025 | Kathryn Guarini director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +1,958 | $0.00 | $0 | 1,958 | Jan 6, 2025 |
| Jan 2, 2025 | Michael S Brown director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +1,958 | $0.00 | $0 | 1,958 | Jan 6, 2025 |
| Dec 16, 2024 | Christopher R. Fenimore SVP Finance & CFO | FTax withholding Common Stock | -491 | $730.81 | $359k | 16,265 | Dec 18, 2024 |
| Dec 16, 2024 | Daniel P Van Plew EVP & General Mgr, Industrial | FTax withholding Common Stock | -969 | $730.81 | $708k | 34,792 | Dec 18, 2024 |
| Dec 16, 2024 | Neil Stahl EVP Research and Development | FTax withholding Common Stock | -304 | $730.81 | $222k | 48,829 | Dec 18, 2024 |
| Dec 16, 2024 | Jason Pitofsky VP Controller | FTax withholding Common Stock | -298 | $730.81 | $218k | 4,664 | Dec 18, 2024 |
| Dec 16, 2024 | Marion McCourt EVP Commercial | FTax withholding Common Stock | -759 | $730.81 | $555k | 14,230 | Dec 18, 2024 |
| Dec 16, 2024 | Andrew J Murphy EVP Research | FTax withholding Common Stock | -1,054 | $730.81 | $770k | 49,074 | Dec 18, 2024 |
| Dec 16, 2024 | Joseph J Larosa EVP General Counsel and Secret | FTax withholding Common Stock | -702 | $730.81 | $513k | 30,075 | Dec 18, 2024 |
| Dec 6, 2024 | Daniel P Van Plew EVP & General Mgr, Industrial | AGrant or award Common Stock | +3,499 | $0.00 | $0 | 36,253 | Dec 10, 2024 |
| Dec 6, 2024 | Jason Pitofsky VP Controller | AGrant or award Common Stock | +907 | $0.00 | $0 | 5,111 | Dec 10, 2024 |
| Dec 6, 2024 | Marion McCourt EVP Commercial | AGrant or award Common Stock | +2,332 | $0.00 | $0 | 15,263 | Dec 10, 2024 |
| Dec 6, 2024 | Andrew J Murphy EVP Research | AGrant or award Common Stock | +3,499 | $0.00 | $0 | 50,620 | Dec 10, 2024 |
| Dec 6, 2024 | Joseph J Larosa EVP General Counsel and Secret | AGrant or award Common Stock | +2,332 | $0.00 | $0 | 31,269 | Dec 10, 2024 |
| Dec 9, 2024 | Neil Stahl EVP Research and Development | FTax withholding Common Stock | -466 | $787.00 | $367k | 49,133 | Dec 10, 2024 |
| Dec 6, 2024 | Christopher R. Fenimore SVP Finance & CFO | AGrant or award Common Stock | +2,591 | $0.00 | $0 | 17,896 | Dec 10, 2024 |
| Dec 9, 2024 | Joseph J Larosa EVP General Counsel and Secret | FTax withholding Common Stock | -492 | $787.00 | $387k | 30,777 | Dec 10, 2024 |
| Dec 9, 2024 | Daniel P Van Plew EVP & General Mgr, Industrial | FTax withholding Common Stock | -492 | $787.00 | $387k | 35,761 | Dec 10, 2024 |
| Dec 9, 2024 | Christopher R. Fenimore SVP Finance & CFO | FTax withholding Common Stock | -1,140 | $787.00 | $897k | 16,756 | Dec 10, 2024 |
| Dec 9, 2024 | Jason Pitofsky VP Controller | FTax withholding Common Stock | -149 | $787.00 | $117k | 4,962 | Dec 10, 2024 |
| Dec 9, 2024 | Andrew J Murphy EVP Research | FTax withholding Common Stock | -492 | $787.00 | $387k | 50,128 | Dec 10, 2024 |
| Dec 9, 2024 | Marion McCourt EVP Commercial | FTax withholding Common Stock | -274 | $787.00 | $216k | 14,989 | Dec 10, 2024 |
| Apr 4, 2024 | Jason Pitofsky VP Controller | GGift Common Stockindirect: By Trust | +89 | $0.00 | $0 | 89 | Dec 10, 2024 |
| Dec 6, 2024 | Marion McCourt EVP Commercial | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +8,981 | $0.00 | $0 | 8,981 | Dec 10, 2024 |
| Dec 6, 2024 | Andrew J Murphy EVP Research | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,472 | $0.00 | $0 | 13,472 | Dec 10, 2024 |
| Dec 6, 2024 | Daniel P Van Plew EVP & General Mgr, Industrial | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,472 | $0.00 | $0 | 13,472 | Dec 10, 2024 |
| Apr 29, 2024 | Jason Pitofsky VP Controller | GGift Common Stockindirect: By Trust | +90 | $0.00 | $0 | 179 | Dec 10, 2024 |
| Dec 6, 2024 | Joseph J Larosa EVP General Counsel and Secret | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +8,981 | $0.00 | $0 | 8,981 | Dec 10, 2024 |
| Dec 6, 2024 | Jason Pitofsky VP Controller | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +3,236 | $0.00 | $0 | 3,236 | Dec 10, 2024 |
| Dec 6, 2024 | Christopher R. Fenimore SVP Finance & CFO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +9,979 | $0.00 | $0 | 9,979 | Dec 10, 2024 |
| Nov 8, 2024 | Andrew J Murphy EVP Research | GGift Common Stock | -1,185 | $0.00 | $0 | 47,121 | Nov 12, 2024 |
| Nov 1, 2024 | Marion McCourt EVP Commercial | MOption exercise Common Stock10b5-1 | +1,000 | $381.40 | $381k | 13,931 | Nov 5, 2024 |
| Nov 1, 2024 | Marion McCourt EVP Commercial | SOpen-market sale Common Stock10b5-1 | -1,000 | $844.61 | $845k | 12,931 | Nov 5, 2024 |
| Nov 1, 2024 | Marion McCourt EVP Commercial | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -1,000 | $0.00 | $0 | 6,000 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Michael S Browndirector
- Bonnie L Basslerdirector
- N Anthony Colesdirector
- Christopher R. FenimoreSVP Finance & CFO
- Joseph L Goldsteindirector
- Kathryn Guarinidirector
- Joseph J LarosaEVP General Counsel and Secret
- Andrew J MurphyEVP Research
- Marion McCourtEVP Commercial
- Jason PitofskyVP Controller
- Neil StahlEVP Research and Development
- Daniel P Van PlewEVP & General Mgr, Industrial
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.